,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['breast']
 presents updated safety results of destiny-breast-03. 11% ild for t-dxd but only one new case during extended follow up 1 in 4 ild cases not resolved t-dxd had great efficacy but we should bear in mind toxicity and manage it early #asco22 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.